AVBP ArriVent BioPharma, Inc. Common Stock
Healthcare$27.94+4.53%ClosedMarket Cap: $1.30B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.72
P/S
0.00
EV/EBITDA
-7.82
DCF Value
$1.05
FCF Yield
-10.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-49.0%
ROA
-41.6%
ROIC
-48.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-46.1M | $-43.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-38.8M | $-35.5M | $— | — |
| FY null | $0.00 | NaN% | $-177.5M | $-166.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-38.3M | $-35.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-33.6M | $-31.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-66.8M | $-64.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-23.7M | $-20.6M | $— | — |
| FY null | $0.00 | NaN% | $-94.3M | $-80.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-24.2M | $-20.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-25.7M | $-21.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-20.7M | $-17.4M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-23.1M | $-21.2M | $-0.63 | — |